Jun 20, 2020
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
May 12, 2020
Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India
Feb 25, 2019
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Feb 19, 2019
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Oct 30, 2018
Glenmark Pharmaceuticals Celebrates the Inauguration of its U.S. Manufacturing Site in Monroe, North Carolina
Sep 12, 2018
Mitra Biotech Announces Partnership with Glenmark Pharmaceuticals to Provide Clinically Relevant Translational Platform Supporting Development of Immuno-Oncology Portfolio
Jun 18, 2018
The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals' Manufacturing Facility in Monroe, North Carolina
Mar 06, 2018
Glenmark Pharmaceutical S.A. to Invest in New Translational Research Group at Biopole Lausanne-Epalinges
Feb 21, 2018
Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea for Ophthalmic Solution Products
Dec 07, 2017
Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342
Dec 07, 2017
Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342
Jun 20, 2017
Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound from APC Therapeutics to Expand Immuno-Oncology Portfolio